Abdul Latif Al Khal

Specialty: Infectious Disease

Location: Global

Tier: UNRANKED

H-Index: 0

Years Active: 0

Hospital Affiliations

• Hamad Medical Corporation - Member

Key Publications

1. "SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity." - Vaccines (Basel) (2021)
2. "Prevalence and microbiological and genetic characteristics of multidrug-resistant Pseudomonas aeruginosa over three years in Qatar." - Antimicrob Steward Healthc Epidemiol (2022)
3. "The epidemiology and microbiological characteristics of infections caused by Gram-negative bacteria in Qatar: national surveillance from the Study for Monitoring of Antimicrobial Resistance Trends (SMART): 2017 to 2019." - JAC Antimicrob Resist (2023)
4. "Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar." - Oman Med J (2022)
5. "Association of bla(VIM-2), bla(PDC-35), bla(OXA-10,) bla(OXA-488) and bla(VEB-9) β-Lactamase Genes with Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa." - Antibiotics (Basel) (2022)

Knowledge Graph Relationships

Abdul Latif Al Khal is a Infectious Disease specialist affiliated with Hamad Medical Corporation. Authored 5 scholarly articles.